419 related articles for article (PubMed ID: 21850690)
1. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
Klintmalm GB; Davis GL; Teperman L; Netto GJ; Washburn K; Rudich SM; Pomfret EA; Vargas HE; Brown R; Eckhoff D; Pruett TL; Roberts J; Mulligan DC; Charlton MR; Heffron TG; Ham JM; Douglas DD; Sher L; Baliga PK; Kinkhabwala M; Koneru B; Abecassis M; Millis M; Jennings LW; Fasola CG
Liver Transpl; 2011 Dec; 17(12):1394-403. PubMed ID: 21850690
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.
Klintmalm GB; Washburn WK; Rudich SM; Heffron TG; Teperman LW; Fasola C; Eckhoff DE; Netto GJ; Katz E
Liver Transpl; 2007 Nov; 13(11):1521-31. PubMed ID: 17969201
[TBL] [Abstract][Full Text] [Related]
4. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
Becker T; Foltys D; Bilbao I; D'Amico D; Colledan M; Bernardos A; Beckebaum S; Isoniemi H; Pirenne J; Jaray J;
Transplantation; 2008 Dec; 86(12):1689-94. PubMed ID: 19104406
[TBL] [Abstract][Full Text] [Related]
5. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.
Kato T; Yoshida H; Sadfar K; Martinez E; Nishida S; Moon J; Madariaga J; Selvaggi G; Levi D; Ruiz P; Schiff E; Tzakis A
Transplant Proc; 2005 Mar; 37(2):1217-9. PubMed ID: 15848674
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.
Kato T; Gaynor JJ; Yoshida H; Montalvano M; Takahashi H; Pyrsopoulos N; Nishida S; Moon J; Selvaggi G; Levi D; Ruiz P; Schiff E; Tzakis A
Transplantation; 2007 Oct; 84(7):829-35. PubMed ID: 17984834
[TBL] [Abstract][Full Text] [Related]
7. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts.
Figueras J; Prieto M; Bernardos A; Rimola A; Suárez F; de Urbina JO; Cuervas-Mons V; Mata Mde L
Transpl Int; 2006 Aug; 19(8):641-8. PubMed ID: 16827681
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
Jain A; Kashyap R; Demetris AJ; Eghstesad B; Pokharna R; Fung JJ
Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
Rostaing L; Cantarovich D; Mourad G; Budde K; Rigotti P; Mariat C; Margreiter R; Capdevilla L; Lang P; Vialtel P; Ortuño-Mirete J; Charpentier B; Legendre C; Sanchez-Plumed J; Oppenheimer F; Kessler M;
Transplantation; 2005 Apr; 79(7):807-14. PubMed ID: 15818323
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
Otero A; Varo E; de Urbina JO; Martín-Vivaldi R; Cuervas-Mons V; González-Pinto I; Rimola A; Bernardos A; Otero S; Maldonado J; Herrero JI; Barrao E; Domínguez-Granados R
Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
14. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
Mastrobuoni S; Ubilla M; Cordero A; Herreros J; Rabago G
Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
Schuller S; Wiederkehr JC; Coelho-Lemos IM; Avilla SG; Schultz C
Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653
[TBL] [Abstract][Full Text] [Related]
16. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
Washburn K; Speeg KV; Esterl R; Cigarroa F; Pollack M; Tourtellot C; Maxwell P; Halff G
Transplantation; 2001 Nov; 72(10):1675-9. PubMed ID: 11726831
[TBL] [Abstract][Full Text] [Related]
17. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.
Berenguer M; Aguilera V; San Juan F; Benlloch S; Rubin A; López-Andujar R; Moya A; Pareja E; Montalva E; Yago M; de Juan M; Mir J; Prieto M
Transplantation; 2010 Dec; 90(11):1204-9. PubMed ID: 21068701
[TBL] [Abstract][Full Text] [Related]
18. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
Nelson DR; Soldevila-Pico C; Reed A; Abdelmalek MF; Hemming AW; Van der Werf WJ; Howard R; Davis GL
Liver Transpl; 2001 Dec; 7(12):1064-70. PubMed ID: 11753908
[TBL] [Abstract][Full Text] [Related]
19. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.
Figueras J; Bernardos A; Prieto M; Gómez M; Rimola A; Ortiz de Urbina J; Cuervas-Mons V; de la Mata M; Dominguez-Granados R
Transplant Proc; 2002 Aug; 34(5):1511-3. PubMed ID: 12176461
[No Abstract] [Full Text] [Related]
20. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
